These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21177747)

  • 41. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
    Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
    Zare S; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
    Downs-Kelly E; Yoder BJ; Stoler M; Tubbs RR; Skacel M; Grogan T; Roche P; Hicks DG
    Am J Surg Pathol; 2005 Sep; 29(9):1221-7. PubMed ID: 16096413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
    Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
    J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A testing algorithm for determination of HER2 status in patients with breast cancer.
    Nichols DW; Wolff DJ; Self S; Metcalf JS; Jacobs D; Kneuper-Hall R; Cate JC
    Ann Clin Lab Sci; 2002; 32(1):3-11. PubMed ID: 11848614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
    Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL
    J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics].
    Li HH; Ma F; Zeng X; Wang JY; Yuan P; Fan Y; Xu BH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(2):76-80. PubMed ID: 21418986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
    Ma Y; Lespagnard L; Durbecq V; Paesmans M; Desmedt C; Gomez-Galdon M; Veys I; Cardoso F; Sotiriou C; Di Leo A; Piccart MJ; Larsimont D
    Clin Cancer Res; 2005 Jun; 11(12):4393-9. PubMed ID: 15958623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0).
    Wilcock D; Sirohi D; Albertson D; Cleary AS; Coleman JF; Jedrzkiewicz J; Mahlow J; Ruano AL; Gulbahce HE
    Arch Pathol Lab Med; 2024 Aug; 148(8):890-897. PubMed ID: 37934954
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome].
    Zhang S; Wang Y; Guo ZM; Zhang H; Xu L; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):686-90. PubMed ID: 25331387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
    Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
    Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.